Galectin sends belapectin pivotal trial plan to FDA; chairman swaps $105.8M debt for equity
The small-cap liver drug developer has $11.7M in cash, guided to last until June 2027, and has not said how it will pay for a registrational cirrhosis study.
Galectin Therapeutics has taken a step towards a pivotal trial of belapectin, submitting the study protocol to the US Food and Drug Administration. The drug is aimed at patients with MASH cirrhosis and portal hypertension. The company disclosed the filing alongside its results for the quarter ended 30 September 2026, published on 16 November.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Galectin Therapeutics Inc ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.